ArticleCancer reports (Hoboken, N.J.)2023

A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.

Po-Jung Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.